Bionovo Initiates Menerba Phase 3 Trial

The primary aims of the study are to determine the safety and efficacy of two doses of Menerba compared to placebo after 12 weeks of treatment.

American pharmaceutical company Bionovo, Inc. announced yesterday that enrollment has started to the Phase 3 pivotal clinical trial evaluating the safety and efficacy of two doses of Menerba? (MF101) among a cohort of postmenopausal women for the treatment of menopausal hot flashes.

The Phase 3, multicenter, double-blind, placebo-controlled, randomized clinical trial evaluating Menerba is currently open for enrollment. A total of 50 clinical sites in the U.S. will enroll 1,200 postmenopausal women between the ages of 40 and 65 years.

Participants will be randomized to Menerba 5g/day, Menerba 10g/day or placebo and treated for 12 weeks.

The primary aims of